Praxis Precision Medicines (NASDAQ:PRAX) Shares Bought Rep. Gilbert Ray Cisneros, Jr.

Key Points

• Rep. Gilbert Ray Cisneros Jr. purchased between $1,001 and $15,000 of Praxis Precision Medicines stock on July 30, according to a disclosure filed September 4.
• Praxis shares opened at $351.81, with a market capitalization of about $9.82 billion. The company recently reported a quarterly loss of $2.87 per share, beating the consensus estimate of a $3.67 loss.
• Analysts maintain a generally positive view, with a consensus “Moderate Buy” rating and a target price of $585.95; institutional investors own approximately 67.84% of the company.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in Praxis Precision Medicines stock on July 30th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 - $50,000 in shares of Mesabi Trust NYSE: MSB on 7/31/2026.
• Purchased $15,001 - $50,000 in shares of Alkermes NASDAQ: ALKS on 7/30/2026.
• Sold $15,001 - $50,000 in shares of Crinetics Pharmaceuticals NASDAQ: CRNX on 7/30/2026.
• Sold $100,001 - $250,000 in shares of Alibaba Group NYSE: BABA on 7/24/2026.
• Sold $1,001 - $15,000 in shares of Adobe NASDAQ: ADBE on 7/24/2026.
• Sold $1,001 - $15,000 in shares of Viavi Solutions NASDAQ: VIAV on 7/21/2026.
• Purchased $1,001 - $15,000 in shares of SailPoint NASDAQ: SAIL on 7/21/2026.
• Purchased $1,001 - $15,000 in shares of Glacier Bancorp NYSE: GBCI on 7/21/2026.
• Sold $1,001 - $15,000 in shares of FedEx NYSE: FDX on 7/21/2026.
• Purchased $1,001 - $15,000 in shares of Marvell Technology NASDAQ: MRVL on 7/17/2026.

Praxis Precision Medicines Price Performance

Praxis Precision Medicines stock opened at $351.81 on Tuesday. The company has a market capitalization of $9.82 billion, a PE ratio of -27.21 and a beta of 2.76. Praxis Precision Medicines, Inc. has a 12-month low of $37.19 and a 12-month high of $392.70. The firm's fifty day moving average is $338.95 and its 200 day moving average is $323.32.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($2.87) earnings per share for the quarter, beating the consensus estimate of ($3.67) by $0.80. Sell-side analysts expect that Praxis Precision Medicines, Inc. will post -13.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the stock. Royal Bank Of Canada reissued an "outperform" rating and set a $462.00 target price (up from $449.00) on shares of Praxis Precision Medicines in a research report on Friday, August 7th. Piper Sandler reissued an "overweight" rating on shares of Praxis Precision Medicines in a report on Monday, July 13th. Robert W. Baird set a $514.00 target price on Praxis Precision Medicines in a research note on Friday, August 7th. Deutsche Bank Aktiengesellschaft restated a "buy" rating and issued a $374.00 target price (down from $420.00) on shares of Praxis Precision Medicines in a research note on Tuesday, June 2nd. Finally, Wells Fargo & Company reiterated a "positive" rating and set a $362.00 price target (up from $323.00) on shares of Praxis Precision Medicines in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Praxis Precision Medicines currently has an average rating of "Moderate Buy" and a consensus target price of $585.95.

Insider Buying and Selling at Praxis Precision Medicines

In other news, Director Jill Desimone sold 11,600 shares of the company's stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $311.32, for a total value of $3,611,312.00. Following the transaction, the director owned 2,337 shares of the company's stock, valued at approximately $727,554.84. This represents a 83.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.00% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in PRAX. California State Teachers Retirement System lifted its holdings in shares of Praxis Precision Medicines by 32,314.1% in the second quarter. California State Teachers Retirement System now owns 8,906,418 shares of the company's stock worth $2,981,780,000 after buying an additional 8,878,941 shares in the last quarter. Janus Henderson Group PLC lifted its stake in Praxis Precision Medicines by 6.8% in the 1st quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company's stock worth $1,113,514,000 after purchasing an additional 218,777 shares in the last quarter. Perceptive Advisors LLC lifted its stake in Praxis Precision Medicines by 2.0% in the 1st quarter. Perceptive Advisors LLC now owns 2,035,986 shares of the company's stock worth $655,974,000 after purchasing an additional 40,000 shares in the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in Praxis Precision Medicines by 13.3% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 1,974,585 shares of the company's stock valued at $83,031,000 after purchasing an additional 231,827 shares during the period. Finally, Orbis Allan Gray Ltd bought a new position in Praxis Precision Medicines in the 4th quarter valued at $369,946,000. Institutional investors own 67.84% of the company's stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California's 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California's 31st Congressional District. He declared candidacy for the 2026 election. Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor's degree in political science from George Washington University in 1994, a master's in business administration from Regis University in 2002, and a master's degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Praxis Precision Medicines

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company's pipeline includes several lead candidates at various stages of development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.